9 March 2022
Newly discovered function of HLTF in Nucleotide Excision Repair (NER) reveals crucial reaction step in this important repair system
HTLF was already known to be involved in the DNA damage response as an important protein for replicating cells in the post replication repair pathway. But new research from the lab of Oncode Investigator Jurgen Marteijn (Erasmus MC) now revealed a completely different key function of it. The scientists uncovered that the RAD5 related translocase HLTF plays a crucial role in Nucleotide Excision Repair (NER) for the active eviction of the damaged DNA. The findings of this study have been published in Molecular Cell today.
8 March 2022
Inaugural lecture Jurgen Marteijn
On Friday, 18th of March 2022, Oncode Investigator Jurgen Marteijn (Erasmus MC) will give his inaugural lecture to officially accept his position as a newly appointed professor of Transcription Stress and the DNA Damage Response at Erasmus MC – Faculty of Erasmus University Rotterdam.
5 March 2022
Oncode Investigators Ruben van Boxtel and Hans Clevers win Ammodo Science Award
Today it has been announced that the research groups Omnes Pro Uno (OPU) from Utrecht University and the Interdisciplinary Hub for Digitalization and Society (iHub) from Radboud University Nijmegen are the winners of the 2022 Ammodo Science Award for groundbreaking research. Each group receives a cash prize of 1.2 million euros that may be used to explore new areas of research.
28 February 2022
Oncode Investigators Jacco van Rheenen and Louis Vermeulen receive Vici grant
Oncode is proud to announce that Oncode Investigators Jacco van Rheenen (Netherlands Cancer Institute) and Louis Vermeulen (Amsterdam UMC) will both receive the Vici grant of 1.5 million euros from the Dutch Research Council (NWO). The Vici grant targets highly experienced researchers who have successfully demonstrated the ability to develop their own innovative lines of research, and to act as coaches for young researchers.
23 February 2022
New drug combinations found for resistant cancers
Researchers have found multiple drug combinations that could be effective therapies for breast, colon, and pancreatic cancer. An international team of researchers tested over 2.000 combinations of cancer drugs that are already used individually to treat patients. They created the world’s largest resource that shows possible effective combinations for further study, published in Nature today.
22 February 2022
Meeting the experts and exploring the advancements of gene editing
After the great success in 2018, the second edition of the Masterclass “Gene editing and its applications 2.0” took place on January 14, 2022. The event was organised with a lot of enthusiasm by Oncode Investigators Jarno Drost & Ruben van Boxtel (both Princess Maxima Center), who invited several experts in this exciting field and set up a practical “design your own” session.
18 February 2022
New research: impact of dietary interventions on cancer treatment
Research groups within the Erasmus MC Transplant Institute, the Princess Máxima Center for Pediatric Oncology and the University Medical Center Groningen are conducting 3 clinical studies into the effect of different types of calorie-restricted diets on various diseases and operations. Recently, all three study protocols have been approved and published and the inclusion of patients and donors is well underway.
9 February 2022
New CPoC grant brings new hope for patients with myeloproliferative neoplasms and bone marrow fibrosis
In single cell analyses of the bone marrow funded through her Oncode base fund, Oncode Investigator Rebekka Schneider and her team initially identified a targetable biomarker (alarmin S100A8/S100A9) that can act as a predictive biomarker and a novel therapeutic target in one. She also published data showing that tasquinimod – an experimental drug – ameliorates the disease in an experimental MF mouse model, the results suggesting that it can act as a disease modifying agent in MF. Now Schneider was awarded an Oncode CPoC grant, and with the support of Oncode’s valorization team, has entered into a global patent license agreement with Active Biotech.
8 February 2022
Oncode Institute and ArgoBio launch Laigo Bio
ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice, researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation. The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR.
3 February 2022
Patiënten en onderzoekers versterken elkaar tijdens Wereldkankerdag
[English tekst & video included] Ieder jaar wordt op 4 februari wereldwijd stilgestaan bij de impact van kanker tijdens Wereldkankerdag. Fundamentele kankeronderzoekers en kankerpatiënten leven in verschillende werelden die elkaar niet vaak ontmoeten. In deze video leggen Inge Reus en Niels Heine, twee deelnemers van Oncode’s Patiënt Perspectief Programma, samen met Oncode Investigator Peter ten Dijke van het Leids Universitair Medisch Centrum uit welke waarde de samenwerking tussen (ex-)patiënten en onderzoekers heeft.
1 February 2022
Hans Clevers starts a new challenge at Roche
As of March 18, Hans Clevers, Oncode Investigator and one of Oncode’s founding scientists, will head Roche Pharmaceutical Research and Early Development (pRED) and become a member of the Corporate Executive Committee at Roche in Basel, Switzerland. In this new role, he will lead research into the development of drugs for a wide variety of diseases. Hans will stay closely connected to the Oncode research community.
31 January 2022
Optimized colorectal cancer (CRC) catalogue available for all researchers
The Colorectal Cancer (CRC) catalogue - a platform on which you can find all the available biomaterials and omics data within the colorectal cancer, small intestinal cancer, and anal cancer clinical studies in the Netherlands ̶ has now been updated and expanded. More than 40 studies are now included, which together make for more than 30,000 biological samples of CRC patients.
Scroll for more